Salvia Officinalis

by | Mar 21, 2018 | Salvia Officinalis

How Can We Help?
You are here:
< Back

Roxatidine acetate is a specific and competitive histamine H2 receptor antagonist drug that is used to treat gastric ulcers, Zollinger–Ellison syndrome, erosive esophagitis, gastro-oesophageal reflux disease, and gastritis.[1][2]

Pharmacodynamic studies showed that 150 mg of roxatidine acetate were optimal in suppressing gastric acid secretion, and that a single bedtime dose of 150 mg was more effective than a dose of 75 mg twice daily in terms of inhibiting nocturnal acid secretion.[1]

It was patented in 1979 and approved for medical use in 1986.[3] It is available in countries including China, Japan, Korea, Germany, Italy, the Netherlands, Greece and South Africa.[2]

Synthesis

ThiemeChemDrug Synthesis:[4] Patent:[5] Sino revised protocols:[6][7][8][9]

The reductive amination between piperidine [110-89-4] (1) and 3-hydroxybenzaldehyde [100-83-4] (2) gives 3-(1-Piperidinylmethyl)phenol [73279-04-6] (3). William ether synthesis with N-(3-Bromopropyl)phthalimide [5460-29-7] (4) gives PC12898565 (5). W.K. deprotection with hydrazine yielded (3-(1-piperidinylmethyl)phenoxy)propylamine [73278-98-5] (6). Heating with glycolic acid [79-14-1] (7) gave the amide (8). Acetylation with acetic anhydride completed the synthesis of (9).

References

  1. ^ a b Murdoch D, McTavish D (August 1991). "Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders". Drugs. 42 (2): 240–260. doi:10.2165/00003495-199142020-00006. PMID 1717223. S2CID 46973503.
  2. ^ a b BioSpectrum Bureau 1 November 2012 Sinhuan's generic heart drug gets production approval
  3. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 444. ISBN 9783527607495.
  4. ^ Castaer, J.; Serradell, MN; TZU-0460. Drugs Fut 1985, 10, 12, 995.
  5. ^ Kenyu Shibata, 7 More », EP0024510 (1983 to Teikoku Hormone Mfg. Co., Ltd.).
  6. ^ Zhang Yang, et al. WO2019075976 (to Beijing Xuansheng Pharmaceutical Co Ltd).
  7. ^ Guo Rongyao & Wang Xiaofeng, CN107698538 (2018 to Inner Mongolia Jingdong Pharmaceutical Co Ltd).
  8. ^ 刘占滨, et al. CN102993121 (2013 to HARBIN PHARMACEUTICAL GROUP SANJING PHARMACEUTICAL CO Ltd).
  9. ^ He Minrong, CN101717363 (2012 to Jiangsu Baosheng Longcheng Pharmaceutical Co Ltd).
Categories
Table of Contents